Matrix metalloproteinases (MMPs) have a role in the pathogenesis of rosacea-associated chronic blepharitis. Doxycycline is largely used as a treatment for recalcitrant chronic blepharitis. It has been shown in vitro that doxycycline inhibits MMPs activation. The aim of this study was to investigate in vivo the effect of doxycycline in modulating MMPs in patients with chronic idiopathic blepharitis.
Methods
Eight patients (6 male, 2 female; mean age 45.7±17.5 years) were included in the study. Doxycycline (100 mg) was administered orally, twice a day, for 2 weeks and once a day for an additional 2 weeks. Clinical signs and symptoms were evaluated and scored (0–3) at baseline and after 4 weeks. Total sign (TSS) and total symptom (TSyS) scores were calculated. Tear samples and conjunctival impression cytologies were collected at baseline and after 4 weeks of treatment to evaluate MMP-9 and TIMP-1 expression and activity.
Results
An improvement in TSS (4.5±1.1 vs 2.7±1.5) and TSyS (6.6±1.3 vs. 3.1±1.9) was observed after 4 weeks, with significant amelioration of hyperemia, marginal blepharitis, and superficial punctuate keratopathy. Zymography revealed a decrease of MMP-9 activity after 4 weeks. MMP-9 mRNA and protein levels did not change, while an upregulation of TIMP-1 expression was observed.
Conclusions
This study suggests that 4-week treatment with doxycycline significantly improved symptoms and signs in patients with chronic blepharitis in association with a decrease in MMP-9 activity. Upregulation of TIMP-1 is proposed as a possible mechanism of MMP-9 inactivation. (Eur J Ophthalmol 2009; 19: 708–16)
AyliffeW.. Blepharitis and meibomian gland dysfunction. In: Smolin and Thoft's The Cornea: Scientific Foundations and Clinical Practice, 4th ed.Philadelphia: Lippincott Williams & Wilkins, 2005; 647–56.
2.
JacksonW.B.. Blepharitis: current strategies for diagnosis and management.Can J Ophthalmol2008; 43: 170–9.
SolomonA., RosenblattM., LiD.Q.Doxycycline inhibition of interleukin-1 in the corneal epithelium.Invest Ophthalmol Vis Sci2000; 41: 2544–57.
5.
LiD.Q., LuoL., ChenZ., KimH.S., SongX.J., PflugfelderS.C.. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells.Exp Eye Res2006; 82: 588–96.
6.
KrakauerT., BuckleyM.. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines.Antimicrob Agents Chemother2003; 47: 3630–3.
7.
SmithV.A., CookS.D.. Doxycycline-a role in ocular surface repair.Br J Ophthalmol2004; 88: 619–25.
8.
VisseR., NagaseH.. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.Circ Res2003; 92: 827–39.
9.
MaskosK.. Crystal structures of MMPs in complex with physiological and pharmacological inhibitors.Biochimie2005; 87: 249–63.
10.
BrewK., DinakarpandianD., NagaseH.. Tissue inhibitors of metalloproteinases: evolution, structure and function.Biochim Biophys Acta2000; 1477: 267–83.
11.
Di GirolamoN., McCluskeyP., LloydA., CoroneoM.T., WakefieldD.. Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells.Invest Ophthalmol Vis Sci2000; 41: 671–9.
12.
KawashimaY., SaikaS., YamanakaO., OkadaY., OhkawaK., OhnishiY.. Immunolocalization of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human subconjunctival tissues.Curr Eye Res1998; 17: 445–51.
13.
SackR.A., ConradiL., KrumholzD., BeatonA., SatheS., MorrisC.. Membrane array characterization of 80 chemokines, cytokines, and growth factors in open- and closed-eye tears: angiogenin and other defense system constituents.Invest Ophthalmol Vis Sci2005; 46: 1228–38.
14.
ArmstrongD.G., JudeE.B.. The role of matrix metalloproteinases in wound healing.J Am Podiatr Med Assoc2002; 92: 12–8.
AfonsoA.A., SobrinL., MonroyD.C., SelzerM., LokeshwarB., PflugfelderS.C.. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea.Invest Ophthalmol Vis Sci1999; 40: 2506–12.
23.
HanemaaijerR., VisserH., KoolwijkP.Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells.Adv Dent Res1998; 12: 114–8.
24.
LokeshwarB.L., SelzerM.G., BlockN.L., Gunja-SmithZ.. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues.Cancer Res1993; 53: 4493–8.
25.
LokeshwarB.L.. MMP inhibition in prostate cancer.Ann NY Acad Sci1999; 878: 271–89.
26.
UittoV.J., FirthJ.D., NipL., GolubL.M.. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes.Ann NY Acad Sci1994; 732: 140–51.
27.
LiD.Q., LokeshwarB.L., SolomonA., MonroyD., JiZ., PflugfelderS.C.. Regulation of MMP-9 production by human corneal epithelial cells.Exp Eye Res2001; 73: 449–59.
28.
SobrinL., LiuZ., MonroyD.C.Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant.Invest Ophthalmol Vis Sci2000; 41: 1703–9.
29.
RozenS., SkaletskyH.. Primer3 on the WWW for general users and for biologist programmers.Methods Mol Biol2000; 132: 365–86.
30.
PfafflM.W., HorganG.W., DempfleL.. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR.Nucleic Acids Res2002; 30: e36.
31.
WilcoxR.R.. New Statistical Procedures for the Social Sciences: Modern Solution to Basic Problems.Hillsdale, NJ: Lawrence Erlbaum Associates, 1987; 316–20.
32.
Del RossoJ.Q., WebsterG.F., JacksonM.Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea.J Am Acad Dermatol2007; 56: 791–802.
33.
Van ZuurenE.J., GraberM.A., HollisS., ChaudhryM., GuptaA.K., GoverM.. Interventions for rosacea.Cochrane Database Syst Rev2005; 3: CD003262.
34.
FowlerJ.F.Jr.. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.J Drugs Dermatol2007; 6: 641–5.
35.
DonaldsonK.E., KarpC.L., DunbarM.T.. Evaluation and treatment of children with ocular rosacea.Cornea2007; 26: 42–6.
36.
StoneD.U., ChodoshJ.. Ocular rosacea: an update on pathogenesis and therapy.Curr Opin Ophthalmol2004; 15: 499–502.
37.
StoneD.U., ChodoshJ.. Oral tetracyclines for ocular rosacea: an evidence-based review of the literature.Cornea2004; 23: 106–9.
38.
DoughertyJ.M., McCulleyJ.P., SilvanyR.E., MeyerD.R.. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci.Invest Ophthalmol Vis Sci1991; 32: 2970–5.
39.
PisellaP.J., BrignoleF., DebbaschC.Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca.Ophthalmology2000; 107: 1841–9.
40.
De PaivaC.S., CorralesR.M., VillarrealA.L.Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye.Exp Eye Res2006; 83: 526–35.
41.
GórskaR., Nedzi-GóraM.. The effects of the initial treatment phase and of adjunctive low-dose doxycycline therapy on clinical parameters and MMP-8, MMP-9, and TIMP-1 levels in the saliva and peripheral blood of patients with chronic periodontitis.Arch Immunol Ther Exp (Warsz)2006; 54: 419–26.
42.
MäättäM., KariO., TervahartialaT.Tear fluid levels of MMP-8 are elevated in ocular rosacea–treatment effect of oral doxycycline.Graefes Arch Clin Exp Ophthalmol2006; 244: 957–62.
43.
BuduneliE., Vardar-SengülS., BuduneliN., AtillaG., WahlgrenJ., SorsaT.. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate.J Periodontol2007; 78: 127–34.
